"Patients suffering from COVID-19 have been found to exhibit dementia-related biomarkers.. The findings of this study suggest a potential link between mild-to-moderate SARS-CoV-2 infection and the initiation or acceleration of brain β-amyloid pathology, and hint at the possibility of an increased future incidence of Alzheimer’s disease subsequent to the COVID-19 pandemic."
A new paper in Cell, “Pioneering discovery and therapeutics at the brain-vascular-immune interface,” describes COVID-19 as a neurological disease alongside multiple sclerosis, Alzheimer’s, stroke and traumatic brain injury.
“COVID-19 can accelerate progression of dementia and induce BBB disruption and inflammatory blood clots causally linked with neuroinflammation and neuronal loss.8 In neurodevelopmental disorders, prematurity and perinatal hypoxia that trigger brain hemorrhage and BBB disruption are risk factors for cerebral palsy, intellectual disability, and autism. Collectively, these risk factors highlight the interconnected vascular and immune triggers of neurological diseases.”
